The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. - Jeong TJ; Lee HT; Gu N; Jang YJ; Choi SB; Park UB; Lee SH; Heo YS (Biomedicines, 2022)